Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08FJL
|
||||
Former ID |
DAP000269
|
||||
Drug Name |
Carbetocin
|
||||
Synonyms |
Carbetocino [INN-Spanish]; Carbetocinum [INN-Latin]; Duratocin (TN); 1-Buttersaeure-2-(3-(4-methoxyphenyl)-L-alanin)oxytocin; 1-{[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-(4-hydroxybenzyl)-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-l-prolyl-l-leucylglycinamide
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Postpartum haemorrhage [ICD9: 666; ICD10:O72] | Approved | [544501] | ||
Therapeutic Class |
Antitocolytic Agents
|
||||
Company |
Pfizer Pharmaceuticals
|
||||
Structure |
Download2D MOL |
||||
Formula |
C45H69N11O12S
|
||||
Canonical SMILES |
CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSCCCC(=O)N(C(C(=O)N1)C<br />C2=CC=C(C=C2)O)C)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O<br />)N)CC(=O)N)CCC(=O)N
|
||||
InChI |
1S/C45H69N11O12S/c1-6-25(4)38-44(67)50-28(15-16-34(46)58)40(63)51-30(21-35(47)59)41(64)53-31(23-69-18-8-10-37(61)55(5)33(43(66)54-38)20-26-11-13-27(57)14-12-26)45(68)56-17-7-9-32(56)42(65)52-29(19-24(2)3)39(62)49-22-36(48)60/h11-14,24-25,28-33,38,57H,6-10,15-23H2,1-5H3,(H2,46,58)(H2,47,59)(H2,48,60)(H,49,62)(H,50,67)(H,51,63)(H,52,65)(H,53,64)(H,54,66)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1
|
||||
InChIKey |
SMMBGKXBHJTULT-DTRKZRJBSA-N
|
||||
CAS Number |
CAS 37025-55-1
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
SuperDrug ATC ID |
H01BB03
|
||||
SuperDrug CAS ID |
cas=037025551
|
||||
Target and Pathway | |||||
Target(s) | Oxytocin receptor | Target Info | Agonist | [535799], [536790], [537867] | |
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
PANTHER Pathway | Oxytocin receptor mediated signaling pathway | ||||
References | |||||
Ref 535799 | Structure and expression of a human oxytocin receptor. Nature. 1992 Apr 9;356(6369):526-9. | ||||
Ref 536790 | Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. | ||||
Ref 537867 | Structural organization of the human oxytocin receptor gene. J Biol Chem. 1994 Dec 23;269(51):32451-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.